Recent Updates
Recently added Catalysts
BRKR Positive Sentiment

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

Tuesday, October 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Bruker Corporation has announced a significant advancement in proteomics with the release of a draft atlas of the human plasma proteome at proteoform resolution. This study, led by Markus Ralser at Charité – Universitätsmedizin Berlin, showcases the capabilities of untargeted timsTOF mass spectrometry. The findings are detailed in a preprint published on bioRxiv.

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a draft atlas of the human plasma proteome.
  • Study conducted by reputable researchers at Charité – Universitätsmedizin Berlin.
  • Utilization of untargeted timsTOF mass spectrometry for detailed analysis.

Full Press Release Details

BERLIN--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. The preprint “A draft atlas of the human plasma proteome at isoform resolution” was posted on September 28, 2026 at https://doi.org/10.64898/2026.09.26.754256. By combining intact protei

Frequently Asked Questions

What is the focus of the Bruker study?

The study focuses on creating a draft atlas of the human plasma proteome at proteoform resolution.

Who conducted the research on the plasma proteome?

The research was conducted by Markus Ralser at Charité – Universitätsmedizin Berlin.

What technology was used in the study?

The study utilized untargeted timsTOF mass spectrometry for detailed proteomic analysis.

When was the preprint published?

The preprint was published on September 28, 2026.

ShareAdd on Google
Tags: BRKR Bruker Corporation timsTOF mass spectrometry proteomics plasma proteome bioRxiv
Last updated: Oct 6, 2026

Biotech snapshot

Cash runway
$185M liquidity · $26M/mo burn
~5 mo
High dilution risk